Loading…
First-in-Human Chronic Implant Experience of the Substernal Extravascular Implantable Cardioverter-Defibrillator
The aim of this study was to evaluate the safety and performance of an extravascular (EV) implantable cardioverter-defibrillator (ICD). Limitations of existing transvenous and subcutaneous ICD systems include lead reliability and morbidity issues associated with ICD lead implantation in the vasculat...
Saved in:
| Published in: | JACC. Clinical electrophysiology 2020-11, Vol.6 (12), p.1525-1536 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c470t-906a3fc99111d7499f4995d3e9b88a62ee8b17cd682a873b4036f138788bfcff3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c470t-906a3fc99111d7499f4995d3e9b88a62ee8b17cd682a873b4036f138788bfcff3 |
| container_end_page | 1536 |
| container_issue | 12 |
| container_start_page | 1525 |
| container_title | JACC. Clinical electrophysiology |
| container_volume | 6 |
| creator | Crozier, Ian Haqqani, Haris Kotschet, Emily Shaw, David Prabhu, Anil Roubos, Nicholas Alison, Jeffrey Melton, Iain Denman, Russell Lin, Tina Almeida, Aubrey Portway, Bridget Sawchuk, Robert Thompson, Amy Sherfesee, Lou Liang, Samuel Lentz, Linnea DeGroot, Paul Cheng, Alan O’Donnell, David |
| description | The aim of this study was to evaluate the safety and performance of an extravascular (EV) implantable cardioverter-defibrillator (ICD).
Limitations of existing transvenous and subcutaneous ICD systems include lead reliability and morbidity issues associated with ICD lead implantation in the vasculature or lack of pacing therapies (e.g., antitachycardia pacing) in subcutaneous systems. The EV defibrillator uses a novel substernal lead placement to address these limitations.
This was a prospective, nonrandomized, chronic pilot study conducted at 4 centers in Australia and New Zealand. Participants were 21 patients referred for ICD implantation. Patients received EV ICD systems. Data collection included major systemic and procedural adverse events, defibrillation testing at implantation, and sensing and pacing thresholds.
Among 20 patients who underwent successful implantation, the median defibrillation threshold was 15 J, and 90% passed defibrillation testing with a ≥10-J safety margin. Mean R-wave amplitude was 3.4 ± 2.0 mV, mean ventricular fibrillation amplitude was 2.8 ± 1.7 mV, and pacing was successful in 95% at ≤10 V. There were no intraprocedural complications. Two patients have undergone elective chronic system removal since hospital discharge. In the 15 patients presently implanted, the systems are stable in long-term follow-up.
This first-in-human evaluation of an EV ICD demonstrated the feasibility of substernal lead placement, defibrillation, and pacing with a chronically implanted system. There were no acute major complications, and pacing, defibrillation, and sensing performance at implantation were successful in most patients. (Extravascular ICD Pilot Study [EV ICD]; NCT03608670)
[Display omitted] |
| doi_str_mv | 10.1016/j.jacep.2020.05.029 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2463102958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405500X20304680</els_id><sourcerecordid>2463102958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-906a3fc99111d7499f4995d3e9b88a62ee8b17cd682a873b4036f138788bfcff3</originalsourceid><addsrcrecordid>eNp9kEtP3TAQRq2KqiDgF1SqsuwmYWzn4Sy6qC5PCYkFrdSd5Thj4au8Onau4N9juMCShWVLcz7PzGHsO4eCA6_PtsXWWFwKAQIKqAoQ7Rd2JEqo8gq4Ovh4w79DdhrCFgB4JZTg5Td2KKXgUnF5xJZLTyHmfsqv19FM2eaB5snb7GZcBjPF7OJxQfI4Wcxml8UHzO7XLkSkyQypGMnsTLDrYOg9YroBs42h3s87pETm5-h8R34YTJzphH11Zgh4-nYfs7-XF3821_nt3dXN5vdtbssGYt5CbaSzbcs575uybV06VS-x7ZQytUBUHW9sXythVCO7EmTt0k6NUp2zzslj9nP_70Lz_xVD1KMPFtMQE85r0KKsJU_WKpVQuUctzSEQOr2QHw09aQ76xbbe6lfb-sW2hkqnXEr9eGuwdiP2H5l3twn4tQcwrbnzSDrYV5O9J7RR97P_tMEzE8WSng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2463102958</pqid></control><display><type>article</type><title>First-in-Human Chronic Implant Experience of the Substernal Extravascular Implantable Cardioverter-Defibrillator</title><source>ScienceDirect (Online service)</source><creator>Crozier, Ian ; Haqqani, Haris ; Kotschet, Emily ; Shaw, David ; Prabhu, Anil ; Roubos, Nicholas ; Alison, Jeffrey ; Melton, Iain ; Denman, Russell ; Lin, Tina ; Almeida, Aubrey ; Portway, Bridget ; Sawchuk, Robert ; Thompson, Amy ; Sherfesee, Lou ; Liang, Samuel ; Lentz, Linnea ; DeGroot, Paul ; Cheng, Alan ; O’Donnell, David</creator><creatorcontrib>Crozier, Ian ; Haqqani, Haris ; Kotschet, Emily ; Shaw, David ; Prabhu, Anil ; Roubos, Nicholas ; Alison, Jeffrey ; Melton, Iain ; Denman, Russell ; Lin, Tina ; Almeida, Aubrey ; Portway, Bridget ; Sawchuk, Robert ; Thompson, Amy ; Sherfesee, Lou ; Liang, Samuel ; Lentz, Linnea ; DeGroot, Paul ; Cheng, Alan ; O’Donnell, David</creatorcontrib><description>The aim of this study was to evaluate the safety and performance of an extravascular (EV) implantable cardioverter-defibrillator (ICD).
Limitations of existing transvenous and subcutaneous ICD systems include lead reliability and morbidity issues associated with ICD lead implantation in the vasculature or lack of pacing therapies (e.g., antitachycardia pacing) in subcutaneous systems. The EV defibrillator uses a novel substernal lead placement to address these limitations.
This was a prospective, nonrandomized, chronic pilot study conducted at 4 centers in Australia and New Zealand. Participants were 21 patients referred for ICD implantation. Patients received EV ICD systems. Data collection included major systemic and procedural adverse events, defibrillation testing at implantation, and sensing and pacing thresholds.
Among 20 patients who underwent successful implantation, the median defibrillation threshold was 15 J, and 90% passed defibrillation testing with a ≥10-J safety margin. Mean R-wave amplitude was 3.4 ± 2.0 mV, mean ventricular fibrillation amplitude was 2.8 ± 1.7 mV, and pacing was successful in 95% at ≤10 V. There were no intraprocedural complications. Two patients have undergone elective chronic system removal since hospital discharge. In the 15 patients presently implanted, the systems are stable in long-term follow-up.
This first-in-human evaluation of an EV ICD demonstrated the feasibility of substernal lead placement, defibrillation, and pacing with a chronically implanted system. There were no acute major complications, and pacing, defibrillation, and sensing performance at implantation were successful in most patients. (Extravascular ICD Pilot Study [EV ICD]; NCT03608670)
[Display omitted]</description><identifier>ISSN: 2405-500X</identifier><identifier>EISSN: 2405-5018</identifier><identifier>DOI: 10.1016/j.jacep.2020.05.029</identifier><identifier>PMID: 33213813</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>anterior mediastinum ; defibrillation ; extravascular ; ICD ; substernal</subject><ispartof>JACC. Clinical electrophysiology, 2020-11, Vol.6 (12), p.1525-1536</ispartof><rights>2020 The Authors</rights><rights>Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-906a3fc99111d7499f4995d3e9b88a62ee8b17cd682a873b4036f138788bfcff3</citedby><cites>FETCH-LOGICAL-c470t-906a3fc99111d7499f4995d3e9b88a62ee8b17cd682a873b4036f138788bfcff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2405500X20304680$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>315,786,790,3568,27957,27958,45815</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33213813$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crozier, Ian</creatorcontrib><creatorcontrib>Haqqani, Haris</creatorcontrib><creatorcontrib>Kotschet, Emily</creatorcontrib><creatorcontrib>Shaw, David</creatorcontrib><creatorcontrib>Prabhu, Anil</creatorcontrib><creatorcontrib>Roubos, Nicholas</creatorcontrib><creatorcontrib>Alison, Jeffrey</creatorcontrib><creatorcontrib>Melton, Iain</creatorcontrib><creatorcontrib>Denman, Russell</creatorcontrib><creatorcontrib>Lin, Tina</creatorcontrib><creatorcontrib>Almeida, Aubrey</creatorcontrib><creatorcontrib>Portway, Bridget</creatorcontrib><creatorcontrib>Sawchuk, Robert</creatorcontrib><creatorcontrib>Thompson, Amy</creatorcontrib><creatorcontrib>Sherfesee, Lou</creatorcontrib><creatorcontrib>Liang, Samuel</creatorcontrib><creatorcontrib>Lentz, Linnea</creatorcontrib><creatorcontrib>DeGroot, Paul</creatorcontrib><creatorcontrib>Cheng, Alan</creatorcontrib><creatorcontrib>O’Donnell, David</creatorcontrib><title>First-in-Human Chronic Implant Experience of the Substernal Extravascular Implantable Cardioverter-Defibrillator</title><title>JACC. Clinical electrophysiology</title><addtitle>JACC Clin Electrophysiol</addtitle><description>The aim of this study was to evaluate the safety and performance of an extravascular (EV) implantable cardioverter-defibrillator (ICD).
Limitations of existing transvenous and subcutaneous ICD systems include lead reliability and morbidity issues associated with ICD lead implantation in the vasculature or lack of pacing therapies (e.g., antitachycardia pacing) in subcutaneous systems. The EV defibrillator uses a novel substernal lead placement to address these limitations.
This was a prospective, nonrandomized, chronic pilot study conducted at 4 centers in Australia and New Zealand. Participants were 21 patients referred for ICD implantation. Patients received EV ICD systems. Data collection included major systemic and procedural adverse events, defibrillation testing at implantation, and sensing and pacing thresholds.
Among 20 patients who underwent successful implantation, the median defibrillation threshold was 15 J, and 90% passed defibrillation testing with a ≥10-J safety margin. Mean R-wave amplitude was 3.4 ± 2.0 mV, mean ventricular fibrillation amplitude was 2.8 ± 1.7 mV, and pacing was successful in 95% at ≤10 V. There were no intraprocedural complications. Two patients have undergone elective chronic system removal since hospital discharge. In the 15 patients presently implanted, the systems are stable in long-term follow-up.
This first-in-human evaluation of an EV ICD demonstrated the feasibility of substernal lead placement, defibrillation, and pacing with a chronically implanted system. There were no acute major complications, and pacing, defibrillation, and sensing performance at implantation were successful in most patients. (Extravascular ICD Pilot Study [EV ICD]; NCT03608670)
[Display omitted]</description><subject>anterior mediastinum</subject><subject>defibrillation</subject><subject>extravascular</subject><subject>ICD</subject><subject>substernal</subject><issn>2405-500X</issn><issn>2405-5018</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kEtP3TAQRq2KqiDgF1SqsuwmYWzn4Sy6qC5PCYkFrdSd5Thj4au8Onau4N9juMCShWVLcz7PzGHsO4eCA6_PtsXWWFwKAQIKqAoQ7Rd2JEqo8gq4Ovh4w79DdhrCFgB4JZTg5Td2KKXgUnF5xJZLTyHmfsqv19FM2eaB5snb7GZcBjPF7OJxQfI4Wcxml8UHzO7XLkSkyQypGMnsTLDrYOg9YroBs42h3s87pETm5-h8R34YTJzphH11Zgh4-nYfs7-XF3821_nt3dXN5vdtbssGYt5CbaSzbcs575uybV06VS-x7ZQytUBUHW9sXythVCO7EmTt0k6NUp2zzslj9nP_70Lz_xVD1KMPFtMQE85r0KKsJU_WKpVQuUctzSEQOr2QHw09aQ76xbbe6lfb-sW2hkqnXEr9eGuwdiP2H5l3twn4tQcwrbnzSDrYV5O9J7RR97P_tMEzE8WSng</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Crozier, Ian</creator><creator>Haqqani, Haris</creator><creator>Kotschet, Emily</creator><creator>Shaw, David</creator><creator>Prabhu, Anil</creator><creator>Roubos, Nicholas</creator><creator>Alison, Jeffrey</creator><creator>Melton, Iain</creator><creator>Denman, Russell</creator><creator>Lin, Tina</creator><creator>Almeida, Aubrey</creator><creator>Portway, Bridget</creator><creator>Sawchuk, Robert</creator><creator>Thompson, Amy</creator><creator>Sherfesee, Lou</creator><creator>Liang, Samuel</creator><creator>Lentz, Linnea</creator><creator>DeGroot, Paul</creator><creator>Cheng, Alan</creator><creator>O’Donnell, David</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202011</creationdate><title>First-in-Human Chronic Implant Experience of the Substernal Extravascular Implantable Cardioverter-Defibrillator</title><author>Crozier, Ian ; Haqqani, Haris ; Kotschet, Emily ; Shaw, David ; Prabhu, Anil ; Roubos, Nicholas ; Alison, Jeffrey ; Melton, Iain ; Denman, Russell ; Lin, Tina ; Almeida, Aubrey ; Portway, Bridget ; Sawchuk, Robert ; Thompson, Amy ; Sherfesee, Lou ; Liang, Samuel ; Lentz, Linnea ; DeGroot, Paul ; Cheng, Alan ; O’Donnell, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-906a3fc99111d7499f4995d3e9b88a62ee8b17cd682a873b4036f138788bfcff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>anterior mediastinum</topic><topic>defibrillation</topic><topic>extravascular</topic><topic>ICD</topic><topic>substernal</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crozier, Ian</creatorcontrib><creatorcontrib>Haqqani, Haris</creatorcontrib><creatorcontrib>Kotschet, Emily</creatorcontrib><creatorcontrib>Shaw, David</creatorcontrib><creatorcontrib>Prabhu, Anil</creatorcontrib><creatorcontrib>Roubos, Nicholas</creatorcontrib><creatorcontrib>Alison, Jeffrey</creatorcontrib><creatorcontrib>Melton, Iain</creatorcontrib><creatorcontrib>Denman, Russell</creatorcontrib><creatorcontrib>Lin, Tina</creatorcontrib><creatorcontrib>Almeida, Aubrey</creatorcontrib><creatorcontrib>Portway, Bridget</creatorcontrib><creatorcontrib>Sawchuk, Robert</creatorcontrib><creatorcontrib>Thompson, Amy</creatorcontrib><creatorcontrib>Sherfesee, Lou</creatorcontrib><creatorcontrib>Liang, Samuel</creatorcontrib><creatorcontrib>Lentz, Linnea</creatorcontrib><creatorcontrib>DeGroot, Paul</creatorcontrib><creatorcontrib>Cheng, Alan</creatorcontrib><creatorcontrib>O’Donnell, David</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>JACC. Clinical electrophysiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crozier, Ian</au><au>Haqqani, Haris</au><au>Kotschet, Emily</au><au>Shaw, David</au><au>Prabhu, Anil</au><au>Roubos, Nicholas</au><au>Alison, Jeffrey</au><au>Melton, Iain</au><au>Denman, Russell</au><au>Lin, Tina</au><au>Almeida, Aubrey</au><au>Portway, Bridget</au><au>Sawchuk, Robert</au><au>Thompson, Amy</au><au>Sherfesee, Lou</au><au>Liang, Samuel</au><au>Lentz, Linnea</au><au>DeGroot, Paul</au><au>Cheng, Alan</au><au>O’Donnell, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First-in-Human Chronic Implant Experience of the Substernal Extravascular Implantable Cardioverter-Defibrillator</atitle><jtitle>JACC. Clinical electrophysiology</jtitle><addtitle>JACC Clin Electrophysiol</addtitle><date>2020-11</date><risdate>2020</risdate><volume>6</volume><issue>12</issue><spage>1525</spage><epage>1536</epage><pages>1525-1536</pages><issn>2405-500X</issn><eissn>2405-5018</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>The aim of this study was to evaluate the safety and performance of an extravascular (EV) implantable cardioverter-defibrillator (ICD).
Limitations of existing transvenous and subcutaneous ICD systems include lead reliability and morbidity issues associated with ICD lead implantation in the vasculature or lack of pacing therapies (e.g., antitachycardia pacing) in subcutaneous systems. The EV defibrillator uses a novel substernal lead placement to address these limitations.
This was a prospective, nonrandomized, chronic pilot study conducted at 4 centers in Australia and New Zealand. Participants were 21 patients referred for ICD implantation. Patients received EV ICD systems. Data collection included major systemic and procedural adverse events, defibrillation testing at implantation, and sensing and pacing thresholds.
Among 20 patients who underwent successful implantation, the median defibrillation threshold was 15 J, and 90% passed defibrillation testing with a ≥10-J safety margin. Mean R-wave amplitude was 3.4 ± 2.0 mV, mean ventricular fibrillation amplitude was 2.8 ± 1.7 mV, and pacing was successful in 95% at ≤10 V. There were no intraprocedural complications. Two patients have undergone elective chronic system removal since hospital discharge. In the 15 patients presently implanted, the systems are stable in long-term follow-up.
This first-in-human evaluation of an EV ICD demonstrated the feasibility of substernal lead placement, defibrillation, and pacing with a chronically implanted system. There were no acute major complications, and pacing, defibrillation, and sensing performance at implantation were successful in most patients. (Extravascular ICD Pilot Study [EV ICD]; NCT03608670)
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33213813</pmid><doi>10.1016/j.jacep.2020.05.029</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2405-500X |
| ispartof | JACC. Clinical electrophysiology, 2020-11, Vol.6 (12), p.1525-1536 |
| issn | 2405-500X 2405-5018 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2463102958 |
| source | ScienceDirect (Online service) |
| subjects | anterior mediastinum defibrillation extravascular ICD substernal |
| title | First-in-Human Chronic Implant Experience of the Substernal Extravascular Implantable Cardioverter-Defibrillator |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T13%3A19%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First-in-Human%20Chronic%20Implant%20Experience%20of%20the%20Substernal%20Extravascular%20Implantable%20Cardioverter-Defibrillator&rft.jtitle=JACC.%20Clinical%20electrophysiology&rft.au=Crozier,%20Ian&rft.date=2020-11&rft.volume=6&rft.issue=12&rft.spage=1525&rft.epage=1536&rft.pages=1525-1536&rft.issn=2405-500X&rft.eissn=2405-5018&rft_id=info:doi/10.1016/j.jacep.2020.05.029&rft_dat=%3Cproquest_cross%3E2463102958%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c470t-906a3fc99111d7499f4995d3e9b88a62ee8b17cd682a873b4036f138788bfcff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2463102958&rft_id=info:pmid/33213813&rfr_iscdi=true |